What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-12-14 compared with 2021-09-14 · 53 added, 26 removed, 17 unchanged (82% of the section changed)

Other Information .

of Amendment to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s

Current Report on Form 8-K on July 6, 2021

by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021

of Change to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s

Current Report on Form 8-K on July 13, 2021

by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021

3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s

Current Report on Form 8-K on June 4, 2021

by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021

4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s

Current Report on Form 8-K on July 6, 2021

by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021

Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to

Section 906 of Sarbanes Oxley Act of 2002

Certification

of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to

Section 906 of Sarbanes Oxley Act of 2002

Underwriting Agreement, dated as of August 9, 2021

Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021.

Articles of Incorporation of the Company, as amended, dated October 31, 2019

Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on March 13, 2020.

of Amendment dated July 2, 2021, to Articles of Incorporation of the Company

Incorporated by reference from the Company’s Current Report on Form 8-K filed on July 6, 2021

Certificate of Change to Articles of Incorporation of the Company, dated July 9, 2021

Incorporated by reference to from the Company’s Current Report on Form 8-K filed on July 13, 2021

Corporate Bylaws

Incorporated by reference from the Company’s Registration Statement on Form SB-2 (File No.

333-68008) filed with the SEC on August 20, 2001.

Amendment No.

1 to the Bylaws of PharmaCyte Biotech, Inc.

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on September 25, 2014.

Amendment No.

2 to the Bylaws of PharmaCyte Biotech, Inc.

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 3, 2014.

Amendment No.

3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on June 4, 2021

Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021

Amendment No.

4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on July 6, 2021

Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021

Form of Common Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Pre-Funded Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Underwriter’s Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Pre-Funded Common Stock Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Form of Series A Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Form of Placement Agent Common Stock Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Securities Purchase Agreement, dated as of August 19, 2021

Incorporated by reference from the Company’s Current Report on Form

8-K filed with the SEC on August 23, 2021.

Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Filed herewith

Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Filed herewith

Certification of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002

Furnished herewith

Certification of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002

Furnished herewith

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

8 unchanged sentences

PharmaCyte Biotech, Inc.

September 14, 2021

December 14, 2021

/s/ Kenneth L.

1 unchanged sentence

(Duly Authorized Officer and Principal Executive Officer)

September 14, 2021

December 14, 2021

/s/ Carlos A.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information